BioCentury
ARTICLE | Clinical News

Tarvacin bavituximab: Phase Ib started

June 12, 2006 7:00 AM UTC

PPHM started a U.S. Phase Ib trial in up to 24 patients with HCV infection. Each cohort will receive 4 doses of bavituximab over a 14-day period and will be followed for an additional 12 weeks. ...